logo-loader
viewCellmid Limited

Cellmid has significant new findings on midkine published in leading medical journal

Recently published study findings show Cellmid’s midkine antibodies prevented heart muscle damage and preserved function.

human heart
Cellmid now plans to validate further findings

Cellmid Ltd (ASX:CDY) has revealed that the prestigious Journal of Experimental Medicine has published a significant study showing for the first time that midkine, around which the company holds extensive intellectual property rights, promotes cardiac muscle inflammation associated with the occasionally fatal autoimmune disease, myocarditis.

Cellmid’s midkine antibodies prevent cardiac muscle damage due to rampant inflammation, thereby reducing fibrosis and preserving cardiac function.

READ: Cellmid becomes profitable in December after achieving record quarterly sales

The paper by Cellmid collaborators Dr Ludwig Weckbach and Professor Barbara Walzog describes how midkine is key to the inflammatory processes of myocarditis leading to cardiomyopathy and end-stage heart failure.

As the holder of the most significant intellectual property assets around midkine globally, the publication provides Cellmid with exposure to and a strong platform for partnerships.

Important further studies planned

The findings of midkine’s role in autoimmune myocarditis may be relevant to the dangerous side effects of new blockbuster cancer drugs that boost the immune system to combat tumours.

By taking the breaks off the immune system, checkpoint inhibitors often cause immune related adverse events that can develop rapidly and, in the case of autoimmune myocarditis, are fatal in about one to four percent of all patients treated with checkpoint inhibitors.

Cellmid head of R&D Dr Graham Robertson said: “The potential of Cellmid’s midkine antibodies to alleviate the heart failure experienced by cancer patients may lead to deploying our midkine assets as an adjunct therapy in oncology to work alongside immuno-oncology drugs.”

READ: Cellmid builds IP for midkine portfolio with new patents

The latest findings and planned future studies support the therapeutic application of Cellmid’s midkine antibodies in the treatment of myocarditis, including myocarditis resulting from injury to the myocardium by toxins, therapeutic agents and other drugs, infectious agents and other autoimmune diseases/conditions.

Quick facts: Cellmid Limited

Price: 0.21 AUD

ASX:CDY
Market: ASX
Market Cap: $18.48 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cellmid Limited named herein, including the promotion by the Company of Cellmid Limited in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Cellmid Limited outlines key components for FY2020 growth strategy

Cellmid Limited (ASX:CDY) chief executive officer and managing director Maria Halasz updates Proactive Investors on the company’s key components for its FY2020 growth strategy, which includes an exciting new global product to assist ageing hair.  Cellmid is a listed company with health...

on 14/8/19

2 min read